Eli Lilly is to buy Prevail Therapeutics, a US biotech focused on developing adeno-associated viral vector 9 (AAV9) gene therapies to treat neurodegenerative diseases, in a deal that could be worth as much as $1.04 billion.
Eli Lilly is wading into gene therapy, inking a deal with Precision BioSciences to develop in vivo gene therapies for three gene targets. The first target will be Duchenne muscular dystrophy, a disease caused by mutations in the dystrophin gene that prevent it from producing a protein of the same name. The other two have not been revealed.
US medical research agency the National Institutes of Health (NIH) has paused a Phase 3 study on Eli Lilly’s Covid-19 antibody treatment on a potential safety concern.
